


### Claims

1. A crystalline form of 1-((2*R*,4*R*)-2-(1*H*-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, having the structure:




and having a powder X-ray diffraction pattern comprising peaks at  $2\theta$  values of: 11.6, 12.1 and  $19.6^\circ 2\theta \pm 0.2^\circ 2\theta$ .

2. The crystalline form of claim 1, having a powder X-ray diffraction pattern comprising peaks at  $2\theta$  values of: 11.6, 12.1, 17.0, 17.7 and  $19.6^\circ 2\theta \pm 0.2^\circ 2\theta$ .
3. The crystalline form of claim 1, having a Raman spectrum comprising wavenumber ( $\text{cm}^{-1}$ ) values of:  $2219 \text{ cm}^{-1} \pm 2 \text{ cm}^{-1}$ .
4. The crystalline form of claim 1, having a Raman spectrum comprising wavenumber ( $\text{cm}^{-1}$ ) values of:  $1612 \text{ cm}^{-1} \pm 2 \text{ cm}^{-1}$ .
5. The crystalline form of claim 1, having a Raman spectrum comprising wavenumber ( $\text{cm}^{-1}$ ) values of: 1612 and  $2219 \text{ cm}^{-1} \pm 2 \text{ cm}^{-1}$ .
6. The crystalline form of claim 1, having a Raman spectrum comprising wavenumber ( $\text{cm}^{-1}$ ) values of: 1534, 1612 and  $2219 \text{ cm}^{-1} \pm 2 \text{ cm}^{-1}$ .
7. The crystalline form of claim 1, having a Raman spectrum comprising wavenumber ( $\text{cm}^{-1}$ ) values of: 1175, 1534, 1612 and  $2219 \text{ cm}^{-1} \pm 2 \text{ cm}^{-1}$ .
8. The crystalline form of claim 1, having a  $^{13}\text{C}$  solid state NMR spectrum comprising resonance (ppm) values of:  $148.3 \text{ ppm} \pm 0.2 \text{ ppm}$ .
9. The crystalline form of claim 1, having a  $^{13}\text{C}$  solid state NMR spectrum comprising resonance (ppm) values of: 57.8, 134.8 and 148.3 ppm  $\pm 0.2 \text{ ppm}$ .


10. The crystalline form of claim 1, having a  $^{13}\text{C}$  solid state NMR spectrum comprising resonance (ppm) values of: 57.8, 134.8, 144.7 and 148.3 ppm  $\pm$  0.2 ppm.

11. A crystalline form of 1-((2*R*,4*R*)-2-(1*H*-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, having the structure:



and having: (a) a powder X-ray diffraction pattern comprising a peak at a  $2\theta$  value of: 11.6 and 12.1  $^{\circ}2\theta \pm 0.2$   $^{\circ}2\theta$ ; and (b) a Raman spectrum comprising wavenumber ( $\text{cm}^{-1}$ ) values of: 1612 and 2219  $\text{cm}^{-1} \pm 2$   $\text{cm}^{-1}$


12. A crystalline form of 1-((2*R*,4*R*)-2-(1*H*-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, having the structure:



and having: (a) a powder X-ray diffraction pattern comprising a peak at a  $2\theta$  value of: 11.6 and 12.1  $^{\circ}2\theta \pm 0.2$   $^{\circ}2\theta$ ; (b) a Raman spectrum comprising wavenumber ( $\text{cm}^{-1}$ ) values of: 1612 and 2219  $\text{cm}^{-1} \pm 2$   $\text{cm}^{-1}$  and (c) a  $^{13}\text{C}$  solid state NMR spectrum comprising a resonance (ppm) value of: 148.3 ppm  $\pm$  0.2 ppm.

13. The crystalline form of claim 1, having: (a) a Raman spectrum comprising wavenumber ( $\text{cm}^{-1}$ ) values of: 1612 and 2219  $\text{cm}^{-1} \pm 2$   $\text{cm}^{-1}$  and (b) a  $^{13}\text{C}$  solid state NMR spectrum comprising a resonance (ppm) value of: 148.3 ppm  $\pm$  0.2 ppm.

14. A crystalline form of 1-((2*R*,4*R*)-2-(1*H*-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, having the structure:



and having: (a) a powder X-ray diffraction pattern comprising a peak at a  $2\theta$  value of: 11.6 and  $12.1^\circ 2\theta \pm 0.2^\circ 2\theta$ ; and (b) a  $^{13}\text{C}$  solid state NMR spectrum comprising a resonance (ppm) value of:  $148.3 \text{ ppm} \pm 0.2 \text{ ppm}$ .

15. A pharmaceutical composition comprising the crystalline form of claim 1, and a pharmaceutically acceptable carrier or excipient.

16. A pharmaceutical composition comprising the crystalline form of claim 11, and a pharmaceutically acceptable carrier or excipient.

17. A pharmaceutical composition comprising the crystalline form of claim 12, and a pharmaceutically acceptable carrier or excipient.

18. A pharmaceutical composition comprising the crystalline form of claim 14, and a pharmaceutically acceptable carrier or excipient.